Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Filters applied: . Clear all
Page 1
Long-term benefits of a therapeutic make-up consultation for patients with various facial dermatoses.
Bonnelye J, Lancien U, Poinas A, Vibet MA, Dreno B. Bonnelye J, et al. Among authors: vibet ma. Eur J Dermatol. 2023 Aug 1;33(4):419-425. doi: 10.1684/ejd.2023.4534. Eur J Dermatol. 2023. PMID: 37823493
BACKGROUND: Therapeutic make-up has previously been proven to be efficacious in improving the quality of life of patients with facial dermatoses, but its efficacy has only been assessed in the short term (less than one month). OBJECTIVES: This study aimed to determine whet …
BACKGROUND: Therapeutic make-up has previously been proven to be efficacious in improving the quality of life of patients with facial dermat …
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit B, Vanhove B, Vibet MA, Le Thuaut A, Lacombe K, Dubee V, Ader F, Ferre V, Vicaut E, Orain J, Le Bras M, Omnes A, Berly L, Jobert A, Morineau-Le Houssine P, Botturi K, Josien R, Flet L, Degauque N, Brouard S, Duvaux O, Poinas A, Raffi F; POLYCOR study group. Gaborit B, et al. Among authors: vibet ma. Trials. 2021 Mar 9;22(1):199. doi: 10.1186/s13063-021-05132-9. Trials. 2021. PMID: 33750432 Free PMC article.
Convalescent plasma to treat infected patients is therefore a relevant therapeutic option currently under assessment (CORIMUNO-PLASM NCT04324047). However, the difficulties of collecting plasma on the long term are not adapted to a broad use across all populations. New pol …
Convalescent plasma to treat infected patients is therefore a relevant therapeutic option currently under assessment (CORIMUNO-PLASM NCT0432 …
Modeling the risk of fluoroquinolone resistance in non-severe community-onset pyelonephritis.
Leforestier A, Vibet MA, Gentet N, Javaudin F, Le Bastard Q, Montassier E, Batard E. Leforestier A, et al. Among authors: vibet ma. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1123-1127. doi: 10.1007/s10096-020-03830-x. Epub 2020 Jan 30. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31997098
A specific model was derived to identify district #2 patients with a low (10% or lower) probability of being infected by a fluoroquinolone resistant isolate. Independent risk factors were residency in long-term care facility (aOR, 3.3 (0.7-13.5)), and in the 6 previous mon …
A specific model was derived to identify district #2 patients with a low (10% or lower) probability of being infected by a fluoroquinolone r …